CAC 40
8 022,41 -0,85 (-0,01 %) Euro Stoxx 50
4 918,09 -18,48 (-0,37 %) Dow Jones
37 911,45 +136,07 (+0,36 %) EUR/USD
1,0653 +0,0007 (+0,06 %) Gold future
2 410,90 +12,90 (+0,54 %) Bitcoin EUR
60 338,50 +1 063,00 (+1,79 %)
AbbVie Inc. (ABBV)
AbbVie Inc.
1 North Waukegan Road
North Chicago, IL 60064-6400
United States
847 932 7900
https://www.abbvie.com
Secteur(s): Healthcare
Secteur d’activité: Drug Manufacturers - General
Employés à temps plein: 50 000
Dirigeants clés
| Nom | Titre | Payer | Exercé | Année de naissance |
|---|---|---|---|---|
| Mr. Richard A. Gonzalez | Chairman & CEO | 7,19M | S.O. | 1954 |
| Mr. Robert A. Michael | President & COO | 4,62M | S.O. | 1970 |
| Mr. Scott T. Reents | Executive VP & CFO | 3,13M | S.O. | 1968 |
| Dr. Azita Saleki-Gerhardt Ph.D. | Executive VP & COO | 3,51M | 5,25M | 1963 |
| Mr. Jeffrey Ryan Stewart | Executive VP & Chief Commercial Officer | 4,32M | 2,13M | 1969 |
| Dr. Thomas J. Hudson M.D. | Senior VP & Chief Scientific Officer of Global Research | S.O. | S.O. | 1962 |
| Ms. Elizabeth Shea | Senior Vice President of Investor Relations | S.O. | S.O. | S.O. |
| Mr. Perry C. Siatis | Executive VP, General Counsel & Secretary | S.O. | S.O. | 1975 |
| Mr. Sanjay Narayan | Senior VP, Chief Ethics, Compliance Officer & Allergan Aesthetic Legal | S.O. | S.O. | S.O. |
| Mr. Timothy J. Richmond | Executive VP & Chief Human Resources Officer | 1,12M | S.O. | 1966 |
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Gouvernance d’entreprise
L’ISS Governance QualityScore de AbbVie Inc. en date du 1 avril 2024 est 8. Les scores principaux sont Audit : 8; Société : 5; Droits des actionnaires : 9; Compensation : 6.
